October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of $35M and ...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
-
-
July 12, 2022 — Biotronik announced the presentation of two studies on the performance of its drug-coated balloon catheter Passeo-18 Lux at this year’s LINC congress in Leipzig, Germany. The BIO REACT ...
-
June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, just one week ...
-
May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a ...
January 27, 2023 — The first US patient has been enrolled at Medstar Washington Hospital Center in the SELUTION4ISR ...
January 27, 2023
January 12, 2023 — Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA ...
January 12, 2023
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent (DC ...
January 02, 2023
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the Stellarex 0.035” OTW Drug-coated ...
January 02, 2023
|
November 28, 2022
November 3, 2022 — Medtronic, a global leader in medical technology, today announced the results of two clinical studies ...
November 03, 2022
October 28, 2022 — SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device ...
October 28, 2022
October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement ...
October 18, 2022
August 23, 2022 — The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial ...
August 23, 2022
July 12, 2022 — Biotronik announced the presentation of two studies on the performance of its drug-coated balloon ...
July 12, 2022
June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...
June 08, 2022
May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 ...
May 27, 2022
May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a ...
May 27, 2022
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...
May 20, 2022
May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...
May 19, 2022© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now